Novartis strikes up to $2 billion deal for Excellergy
Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2…
Novartis agrees to acquire Excellergy, Inc., building on
– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases – Lead asset Exl-111 builds…
Novartis strikes up to $2 billion deal for Excellergy
Swiss drugmaker Novartis has agreed to acquire California-based biotech firm Excellergy in a deal worth up to US$2…
Novartis acquires Excellergy for $2 billion
Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company…
Roche’s Strategic Pivot Gains Momentum from Immunology and Capital Restructuring
Roche reports strong Phase III lupus data for Gazyva and finalizes share conversion. The company also increased its…
Novartis Inks Up-to-$5.7B Second Collaboration with Monte Rosa
Nearly a year after licensing Monte Rosa Therapeutics’ Phase II-bound autoimmune disease candidate MRT-6160, Novartis has agreed to…
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
The deal marks the second time Novartis has tapped Monte Rosa’s services in just under year. Taljat David…